Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06500273 · ClinicalTrials.gov registry record · Phase 2
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A Phase 2 study of Large B-cell Lymphoma, sponsored by Allogene Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06500273 is a Phase 2 study of Large B-cell Lymphoma that is actively recruiting participants, run by Allogene Therapeutics. The registered enrollment target is 250 participants, above the 150-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (67% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT06500273, a Phase 2 study of Large B-cell Lymphoma, is actively recruiting participants, sponsored by Allogene Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- GENETIC cemacabtagene ansegedleucel
- DEVICE Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Study Locations (20)
California
- Alta Bates Summit Medical Center - Berkeley
- City of Hope - Duarte
- Cedars-Sinai Medical Center - Los Angeles
- University of California, Los Angeles - Los Angeles
- University of California, Davis Comprehensive Cancer Center - Sacramento
- University of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
Florida
- Miami Cancer Institute at Baptist Health, Inc. - Miami
- Advent Health Cancer Institute - Orlando
- Orlando Health Cancer Institute - Orlando
- Moffitt Cancer Center - Tampa
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Arkansas
- Genesis Cancer and Blood Institute - Hot Springs
Colorado
- Rocky Mountain Cancer Centers - Denver
Delaware
- Medical Oncology Hematology Consultants - Newark
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Georgia
- Augusta University Georgia Cancer Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-06-18 |
| Est. Completion | 2032-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06500273
The ClinicalTrials.gov registry entry for NCT06500273 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 150-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (67% higher). The listed sponsor is Allogene Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT06500273 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06500273 about?
NCT06500273 is a clinical study titled "Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL". This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ In...
What is the current status of trial NCT06500273?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2024-06-18. Estimated completion is 2032-12.
What conditions does trial NCT06500273 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma.
What interventions are being tested in trial NCT06500273?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), cemacabtagene ansegedleucel (GENETIC), Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™ (DEVICE).
Who is sponsoring clinical trial NCT06500273?
This trial is sponsored by Allogene Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06500273 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
CAR-T Followed by Bispecific Antibodies
RECRUITING · Phase 2
-
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
RECRUITING · Phase 2
-
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.